<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987699</url>
  </required_header>
  <id_info>
    <org_study_id>Unique Protocol ID: HCC-S026</org_study_id>
    <nct_id>NCT02987699</nct_id>
  </id_info>
  <brief_title>Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil</brief_title>
  <official_title>Phase II Study of Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin,Leucovorin and 5-Fluorouracil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase II study is to determine the recommended dose, as well as the
      safety and efficacy of the combination of oxaliplatin, leucovorin and 5-Fu introduced by
      hepatic arterial infusion chemotherapy (HAIC) in patients with advanced hepatocellular
      carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of our preliminary pilot study suggested that the combination of oxaliplatin,
      leucovorin and 5-Fu introduced by hepatic arterial infusion chemotherapy (HAIC) may improve
      the survivals for advanced stage HCC. Thus, the investigators carried out this prospective
      randomized control study to determine the recommended dose as well as the safety and
      efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 Months</time_frame>
    <description>Tumor response evaluated by postoperative CT/MRI scan according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of adverse events. Postoperative adverse events were graded based on CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of of Patients developed Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of of patients who developed adverse event. Postoperative adverse events were graded based on CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>HepatoCellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Full Dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full Dosage Chemotherapy regimen administered by HAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dosage of 5-Fu</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose of 5-Fu Chemotherapy regimen administered by HAI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dosage of oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose of oxaliplatin Chemotherapy regimen administered by HAI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fu, oxaliplatin , leucovorin</intervention_name>
    <description>Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2</description>
    <arm_group_label>Full Dosage</arm_group_label>
    <other_name>Full dose Folfox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fu, oxaliplatin , leucovorin</intervention_name>
    <description>Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2</description>
    <arm_group_label>Low Dosage of 5-Fu</arm_group_label>
    <other_name>Low dose 5-Fu Folfox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fu, oxaliplatin , leucovorin</intervention_name>
    <description>Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2</description>
    <arm_group_label>Low Dosage of oxaliplatin</arm_group_label>
    <other_name>Low dose oxaliplatin Folfox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
        Association for the Study of the Liver (EASL) Patients must have at least one tumor lesion
        that can be accurately measured according to EASL criteria.

        diagnosed with major or main portal vein invasion (Vp3 or Vp4) KPS≥70； with no previous
        treatment No Cirrhosis or cirrhotic status of Child-Pugh class A only Not amendable to
        surgical resection ,local ablative therapy and any other cured treatment.

        The following laboratory parameters:

        Platelet count ≥ 75,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥
        30 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of
        normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) &gt;1,500/mm3
        Ability to understand the protocol and to agree to and sign a written informed consent
        document

        Exclusion Criteria:

        Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic
        encephalopathy Known history of HIV History of organ allograft Known or suspected allergy
        to the investigational agents or any agent given in association with this trial.

        Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Evidence of bleeding
        diathesis. Patients with clinically significant gastrointestinal bleeding within 30 days
        prior to study entry.

        Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study
        drug Serious non-healing wound, ulcer, or bone fracture Known central nervous system tumors
        including metastatic brain disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Hepatobiliary Pancreatic Oncology of Sun Yat-sen University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi, Doctor</last_name>
    <phone>(8620)-87343938</phone>
    <email>shiming@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD.</last_name>
      <email>shiming@sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>shi Ming, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429-42. Review.</citation>
    <PMID>12540794</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>December 27, 2016</last_update_submitted>
  <last_update_submitted_qc>December 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>optimal dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

